Home   ->   news   ->   Press Releases

Press Releases

WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA

SHANGHAI, Oct. 23, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients.

"We commend TaiMed's great progress in advancing this important life-saving therapy," said Dr. Ge Li, Chairman and CEO of WuXi. "This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China."

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. Please visit http://www.wuxiapptec.com.

For further information please contact:

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com

back to top